Results for tag: "Ponatinib"

Ponatinib is a tyrosine kinase inhibitor used to treat certain types of leukemia. It is used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is used when other treatments have failed or are not tolerated. Ponatinib works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Ponatinib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is the only tyrosine kinase inhibitor approved for the treatment of Ph+ ALL. It is also the only drug approved for the treatment of CML in patients who have the T315I mutation. The ponatinib market is highly competitive, with several companies offering similar products. Some of the major players in the market include Bristol-Myers Squibb, Novartis, Pfizer, and Teva Pharmaceuticals. Other companies such as Sun Pharmaceuticals, Cipla, and Dr. Reddy's Laboratories also offer ponatinib products. Show Less Read more